0001209191-23-035984.txt : 20230609
0001209191-23-035984.hdr.sgml : 20230609
20230609174112
ACCESSION NUMBER: 0001209191-23-035984
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230607
FILED AS OF DATE: 20230609
DATE AS OF CHANGE: 20230609
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ildstad Suzanne
CENTRAL INDEX KEY: 0001845822
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40384
FILM NUMBER: 231006547
MAIL ADDRESS:
STREET 1: C/O TALARIS THERAPEUTICS, INC.
STREET 2: 93 WORCESTER STREET, SUITE 120
CITY: WELLESLEY
STATE: MA
ZIP: 02481
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Talaris Therapeutics, Inc.
CENTRAL INDEX KEY: 0001827506
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 570 PRESTON ST.
STREET 2: SUITE 400
CITY: LOUISVILLE
STATE: KY
ZIP: 40202
BUSINESS PHONE: 502-398-9250
MAIL ADDRESS:
STREET 1: 93 WORCESTER STREET
CITY: WELLESLEY
STATE: MA
ZIP: 02481
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-06-07
0
0001827506
Talaris Therapeutics, Inc.
TALS
0001845822
Ildstad Suzanne
C/O TALARIS THERAPEUTICS, INC.
570 S. PRESTON ST.
LOUISVILLE
KY
40202
1
0
0
0
1
Common Stock
2023-06-07
4
S
0
75001
2.3879
D
3881473
D
Common Stock
2023-06-08
4
S
0
40642
2.4795
D
3840831
D
Common Stock
2023-06-09
4
S
0
25419
2.4642
D
3815412
D
Common Stock
654205
I
See footnote
Common Stock
654205
I
See footnote
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.26 to $2.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
1,200,000 shares previously reported as owned through the Reporting Persons GRAT are now included in shares reported as directly owned. Such transfer was made in accordance with the exemption afforded under Rule 16a-13 of the Securities Exchange Act of 1934, as amended.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.42 to $2.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 to $2.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
These shares are held in a trust for the benefit of the Reporting Person's son. The Reporting Person's son is co-trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
These shares are held in a trust for the benefit of the Reporting Person's daughter. The Reporting Person's daughter is co-trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
/s/ Mary Kay Fenton, attorney-in-fact
2023-06-09